About
Bortezomib is a potent, reversible proteasome inhibitor that plays a crucial role in the treatment of certain hematologic malignancies. It works by inhibiting the 26S proteasome, a multi-catalytic proteinase complex responsible for degrading ubiquitinated proteins. This inhibition disrupts various cellular processes, including cell cycle progression, apoptosis, and angiogenesis, leading to the accumulation of misfolded proteins and ultimately inducing programmed cell death in cancer cells. Its mechanism of action makes it particularly effective against plasma cell disorders like multiple myeloma and certain lymphomas.
Clinically, bortezomib is administered intravenously or subcutaneously. Its efficacy has been demonstrated in both newly diagnosed and relapsed/refractory settings, often in combination with other chemotherapeutic agents or corticosteroids. The drug's targeted action helps to selectively eliminate malignant cells while minimizing damage to healthy tissues, although systemic side effects can occur due to the ubiquitous nature of proteasome activity. Regular monitoring of patient response and adverse events is essential throughout the treatment course.
Uses
- Treatment of multiple myeloma.
- Management of relapsed or refractory multiple myeloma.
- Treatment of mantle cell lymphoma.
- Used in combination with other anti-cancer agents.
Directions For Use
Administered intravenously or subcutaneously by a healthcare professional. Dosage and schedule are determined by the physician based on the patient's condition.
Benefits
- Effective in treating multiple myeloma.
- Induces apoptosis in cancer cells.
- Can be used in relapsed/refractory cases.
- Improves progression-free survival.
- Offers a targeted approach to cancer therapy.
- Available for both IV and subcutaneous administration.
Side Effects
- Peripheral neuropathy
- Thrombocytopenia
- Neutropenia
- Fatigue
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Fever
- Anemia
- Rash
- Hypotension
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects like liver toxicity or gastrointestinal issues.
- Pregnancy - Bortezomib is contraindicated in pregnancy due to potential fetal harm. Effective contraception is required for patients of reproductive potential.
- Breastfeeding - Breastfeeding is not recommended during treatment with bortezomib and for a period after the last dose, due to potential excretion into breast milk.
- Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustments may be necessary due to altered drug metabolism.
- Kidney - Generally, no dose adjustment is required for mild to moderate renal impairment, but caution is advised in severe cases.
- Lung - Monitor for new or worsening pulmonary symptoms, as acute diffuse infiltrative pulmonary disease has been reported.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!